The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer

John Kaczmar, Ranee Mehra

Research output: Contribution to journalReview article

Abstract

Research over the last decade has determined that the gene rearrangement involving the anaplastic lymphoma kinase (ALK) gene is an oncogenic driver in approximately 5% of patients with non-small cell lung carcinoma (NSCLC). This review describes the discovery of the ALK translocation, development of ALK directed therapy, and acquired resistance to ALK directed therapy with a focus on the clinical data and efficacy of the most recently approved ALK inhibitor, ceritinib.

Original languageEnglish (US)
Pages (from-to)236-241
Number of pages6
JournalTherapeutic Advances in Respiratory Disease
Volume9
Issue number5
DOIs
StatePublished - Oct 2015

    Fingerprint

Keywords

  • ALK translocation
  • NSCLC
  • ceritinib

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)

Cite this